Jcovden (previously COVID-19 Vaccine Janssen)

On 26 July 2024, the European Commission withdrew the marketing authorisation for Jcovden (COVID19 Vaccine Janssen (Ad26.COV2.S)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Janssen-Cilag International N.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Jcovden was granted conditional marketing authorisation in the EU on 11 March 2021 for active immunisation against coronavirus disease 2019 (COVID-19). The conditional marketing authorisation was switched to a standard marketing authorisation, valid for 5 years, on 09 January 2023. The European Public Assessment Report (EPAR) for Jcovden is updated to indicate that the marketing authorisation is no longer valid.